Working Towards a Treat-to-Target Protocol in Juvenile Proliferative Lupus Nephritis - A Survey of Pediatric Rheumatologists and Nephrologists in Germany and Austria.
SLE
T2T
corticosteroid
cyclophosphamide
kidney biopsy
mycophenolate mofetil
nephritis
Journal
Frontiers in pediatrics
ISSN: 2296-2360
Titre abrégé: Front Pediatr
Pays: Switzerland
ID NLM: 101615492
Informations de publication
Date de publication:
2022
2022
Historique:
received:
10
01
2022
accepted:
07
03
2022
entrez:
9
5
2022
pubmed:
10
5
2022
medline:
10
5
2022
Statut:
epublish
Résumé
To describe treatment practices for juvenile proliferative lupus nephritis (LN) class III and IV of pediatric rheumatologists and nephrologists in Germany and Austria in preparation for a treat-to-target treatment protocol in LN. Survey study by members of the Society for Pediatric and Adolescent Rheumatology (GKJR) and the German Society for Pediatric Nephrology (GPN) on diagnostics and (concomitant) therapy of LN. Fifty-eight physicians completed the survey. Overall, there was a considerable heterogeneity regarding the suggested diagnostics and management of juvenile proliferative LN. Increased urinary protein excretion, either assessed by 24 h urine collection or spot urine (protein-creatinine ratio), and reduced estimated glomerular filtration rate were specified as important parameters for indication of kidney biopsy to diagnose proliferative LN and monitoring of therapy. Corticosteroids were generally proposed for induction and maintenance therapy, most often in conjunction with either mycophenolate mofetil (MMF) or cyclophosphamide (CP) as steroid-sparing immunosuppressants. MMF was clearly preferred over CP for induction therapy of LN class III, whereas CP and MMF were equally proposed for LN class IV. MMF was most often recommended for maintenance therapy in conjunction with oral corticosteroids and continued for at least 3 years and 1 year, respectively, after remission. Hydroxychloroquine was widely accepted as a concomitant measure followed by renin-angiotensin system inhibitors in cases of arterial hypertension and/or proteinuria. The majority of pediatric rheumatologists and nephrologists in Germany and Austria propose the use of corticosteroids, most often in combination with either MMF or CP, for treatment of proliferative LN in children. The considerable heterogeneity of responses supports the need for a treat-to-target protocol for juvenile proliferative LN between pediatric rheumatologists and nephrologists.
Sections du résumé
Background
UNASSIGNED
To describe treatment practices for juvenile proliferative lupus nephritis (LN) class III and IV of pediatric rheumatologists and nephrologists in Germany and Austria in preparation for a treat-to-target treatment protocol in LN.
Methods
UNASSIGNED
Survey study by members of the Society for Pediatric and Adolescent Rheumatology (GKJR) and the German Society for Pediatric Nephrology (GPN) on diagnostics and (concomitant) therapy of LN.
Results
UNASSIGNED
Fifty-eight physicians completed the survey. Overall, there was a considerable heterogeneity regarding the suggested diagnostics and management of juvenile proliferative LN. Increased urinary protein excretion, either assessed by 24 h urine collection or spot urine (protein-creatinine ratio), and reduced estimated glomerular filtration rate were specified as important parameters for indication of kidney biopsy to diagnose proliferative LN and monitoring of therapy. Corticosteroids were generally proposed for induction and maintenance therapy, most often in conjunction with either mycophenolate mofetil (MMF) or cyclophosphamide (CP) as steroid-sparing immunosuppressants. MMF was clearly preferred over CP for induction therapy of LN class III, whereas CP and MMF were equally proposed for LN class IV. MMF was most often recommended for maintenance therapy in conjunction with oral corticosteroids and continued for at least 3 years and 1 year, respectively, after remission. Hydroxychloroquine was widely accepted as a concomitant measure followed by renin-angiotensin system inhibitors in cases of arterial hypertension and/or proteinuria.
Conclusion
UNASSIGNED
The majority of pediatric rheumatologists and nephrologists in Germany and Austria propose the use of corticosteroids, most often in combination with either MMF or CP, for treatment of proliferative LN in children. The considerable heterogeneity of responses supports the need for a treat-to-target protocol for juvenile proliferative LN between pediatric rheumatologists and nephrologists.
Identifiants
pubmed: 35529329
doi: 10.3389/fped.2022.851998
pmc: PMC9072733
doi:
Types de publication
Journal Article
Langues
eng
Pagination
851998Informations de copyright
Copyright © 2022 Vollbach, Schuetz, Hedrich, Speth, Mönkemöller, Brunner, Neudorf, Rietschel, Hospach, Kallinich, Hinze, Wagner, Tönshoff, Weber, Latta, Thumfart, Bald, Wiemann, Zappel, Tenbrock and Haffner.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Lupus. 2005;14(12):947-52
pubmed: 16425574
Pediatr Nephrol. 2015 Jul;30(7):1099-106
pubmed: 25190492
Clin Immunol. 2019 Dec;209:108274
pubmed: 31678365
PLoS One. 2018 Jun 28;13(6):e0199003
pubmed: 29953444
Mod Rheumatol. 2018 May;28(3):523-529
pubmed: 28753077
Ann Rheum Dis. 2012 Nov;71(11):1771-82
pubmed: 22851469
J Pediatr. 2005 May;146(5):648-53
pubmed: 15870669
Arthritis Care Res (Hoboken). 2012 Jun;64(6):797-808
pubmed: 22556106
Rheumatology (Oxford). 2016 Sep;55(9):1623-30
pubmed: 27247433
Ann Rheum Dis. 1987 Aug;46(8):617-23
pubmed: 3310927
Neth J Med. 2012 May;70(4):199-207
pubmed: 22641632
Clin J Am Soc Nephrol. 2017 May 8;12(5):825-835
pubmed: 27821390
Pediatr Rheumatol Online J. 2015 Jun 19;13:26
pubmed: 26087651
Expert Rev Clin Immunol. 2011 Mar;7(2):227-41
pubmed: 21426260
Pediatr Rheumatol Online J. 2021 Aug 30;19(1):137
pubmed: 34461932
Pediatr Nephrol. 2020 Jul;35(7):1235-1246
pubmed: 32193650
Ann Rheum Dis. 2020 Jun;79(6):713-723
pubmed: 32220834
Pediatr Rheumatol Online J. 2018 Jan 22;16(1):7
pubmed: 29357887
Lupus. 2013 May;22(6):574-82
pubmed: 23632989
Arthritis Rheum. 2013 Mar;65(3):753-63
pubmed: 23203603
J Nephropathol. 2013 Jan;2(1):71-2
pubmed: 24475428
Pediatr Rheumatol Online J. 2020 Feb 17;18(1):17
pubmed: 32066461
Lupus. 2005;14(4):288-92
pubmed: 15864915
Lupus. 2006;15(4):198-206
pubmed: 16686258
Cancer. 1992 Dec 1;70(11):2703-12
pubmed: 1423201
Arthritis Rheumatol. 2017 Jun;69(6):1267-1271
pubmed: 28235250
Nephrol Dial Transplant. 2013 Jan;28(1):106-11
pubmed: 22764193
Ann Rheum Dis. 2014 Jun;73(6):958-67
pubmed: 24739325
Pediatrics. 2017 Sep;140(3):
pubmed: 28827377
Arthritis Rheum. 2002 Aug;46(8):2121-31
pubmed: 12209517
Arthritis Care Res (Hoboken). 2012 Mar;64(3):375-83
pubmed: 22162255
J Rheumatol. 1994 Nov;21(11):2046-51
pubmed: 7869308
Lupus. 2018 Nov;27(13):2020-2028
pubmed: 30246602
Am J Nephrol. 2014;40(2):105-12
pubmed: 25096639
Int J Rheum Dis. 2018 Jun;21(6):1287-1292
pubmed: 29879312
Pediatr Rheumatol Online J. 2018 Jun 25;16(1):40
pubmed: 29940960
Int J Rheum Dis. 2018 Jan;21(1):200-207
pubmed: 28901731
Clin Exp Rheumatol. 2013 Jan-Feb;31(1):62-8
pubmed: 22935463
Front Med (Lausanne). 2021 Feb 16;8:622225
pubmed: 33665199
Ann Rheum Dis. 2017 Dec;76(12):1965-1973
pubmed: 28877866
Eur J Rheumatol. 2018 Jul;5(2):118-126
pubmed: 30185361
Arthritis Rheum. 1997 Sep;40(9):1725
pubmed: 9324032
Lupus. 2013 Oct;22(11):1135-41
pubmed: 23995863
Ann Rheum Dis. 2018 Jun;77(6):819-828
pubmed: 29643108
Nat Rev Dis Primers. 2020 Jan 23;6(1):7
pubmed: 31974366
Ann Rheum Dis. 2009 Feb;68(2):234-7
pubmed: 18718989
Ann Rheum Dis. 2017 Nov;76(11):1788-1796
pubmed: 28630236
Lupus. 2008 Jun;17(6):596-604
pubmed: 18539716
J Rheumatol. 2017 Jul;44(7):1032-1038
pubmed: 28507183
Kidney Int. 2021 Oct;100(4):753-779
pubmed: 34556300
Lupus. 2019 Apr;28(5):613-620
pubmed: 30871425
Arthritis Rheum. 2012 Jul;64(7):2356-65
pubmed: 22294381
J Rheumatol. 2017 Nov;44(11):1619-1623
pubmed: 28916546
Rheumatology (Oxford). 2013 May;52(5):847-55
pubmed: 23287364
Pediatr Rheumatol Online J. 2017 Nov 7;15(1):78
pubmed: 29116003
Ann Rheum Dis. 1998 Aug;57(8):456-9
pubmed: 9797549
Pediatr Rheumatol Online J. 2018 Oct 22;16(1):65
pubmed: 30348175
Nefrologia. 2012;32 Suppl 1:1-35
pubmed: 22293933
Clin Exp Nephrol. 2005 Mar;9(1):79-84
pubmed: 15830279